amlodipine has been researched along with Body Weight in 47 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Background Amlodipine is a widely used antihypertensive agent for the treatment of paediatric hypertension, but the commercially available tablets are not suitable to treat young patients, who need lower, flexible dosages and a liquid formulation." | 9.34 | Use of amlodipine oral solution for the treatment of hypertension in children. ( Cransberg, K; de Winter, BCM; Hanff, LM; Schreuder, MF; van der Vossen, AC; van Rooij-Kouwenhoven, RWG; Vulto, AG, 2020) |
| " The aim of this study was to evaluate the effects of a fixed-dose olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation compared to singles monotherapies." | 9.19 | Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2014) |
| " This study evaluated the effects of an olmesartan/amlodipine single pill combination compared to olmesartan or amlodipine monotherapies on BP, lipid profile, insulin resistance, and insulin sensitivity parameters." | 9.17 | Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2013) |
| "The authors studied the efficacy and safety of a long half-life dihydropyridine calcium-antagonist--amlodipine--in a single daily dose in the treatment of isolated systolic hypertension in the elderly." | 9.07 | [Amlodipine in isolated systolic hypertension in the aged]. ( Cosentino, N; Mariani, L; Marino, M; Torrisi, G, 1993) |
| "SHR/NDmcr-cp (SHRcp), a rat model of human metabolic syndrome, were divided into four groups, and were administered (i) vehicle, (ii) candesartan (an ARB) 0." | 7.78 | Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Ogawa, H; Sueta, D; Toyama, K; Yamamoto, E; Yasuda, O, 2012) |
| "These data suggest that cilnidipine suppressed the development of proteinuria greater than amlodipine possibly through inhibiting N-type calcium channel-dependent podocyte injury in SHR/ND." | 7.76 | Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. ( Asanuma, K; Fan, YY; Fujita, T; Hitomi, H; Kobori, H; Kohno, M; Nakano, D; Nishiyama, A; Noma, T; Ohashi, N; Ohsaki, H; Suwarni, D; Tomino, Y, 2010) |
| "Although calcium channel blockers have not been shown to be beneficial for the treatment of patients with heart failure, a recent clinical trial demonstrated a favorable effect of amlodipine on the survival of patients with heart failure resulting from nonischemic dilated cardiomyopathy." | 7.69 | Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. ( Matsui, S; Matsumori, A; Okada, I; Sasayama, S; Sato, Y; Shioi, T; Shiota, K; Suzuki, H; Wang, WZ; Yamada, T, 1997) |
| " The pressor response to norepinephrine and angiotensin II, as well as several other blood pressure modulating factors, were studied in normal subjects (n = 9) and patients with essential hypertension (n = 10) before and after 8 weeks of treatment with the long-acting dihydropyridine amlodipine." | 7.68 | Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II. ( Beretta-Piccoli, C; Bühler, FR; Donati, L; Heinen, G; Kusch, F, 1992) |
| "Seventy type 2 diabetes mellitus patients with hypertension were enrolled and randomly divided into two groups." | 6.74 | Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohira, M; Oyama, T; Saiki, A; Shirai, K; Yamaguchi, T, 2009) |
| "Arthritis and hypertension are frequent comorbidities in the elderly hypertensive population." | 6.69 | Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. ( Anderson, A; Bertram, D; Morgan, TO, 2000) |
| "Hypercholesterolemia is a common accompaniment of atherosclerosis and may be associated with cardiac hypertrophy." | 5.35 | Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. ( Kang, BY; Mehta, JL; Palade, P; Sharma, SG; Wang, W, 2009) |
| "Background Amlodipine is a widely used antihypertensive agent for the treatment of paediatric hypertension, but the commercially available tablets are not suitable to treat young patients, who need lower, flexible dosages and a liquid formulation." | 5.34 | Use of amlodipine oral solution for the treatment of hypertension in children. ( Cransberg, K; de Winter, BCM; Hanff, LM; Schreuder, MF; van der Vossen, AC; van Rooij-Kouwenhoven, RWG; Vulto, AG, 2020) |
| "Amlodipine orotate was prepared by reacting orotic acid and amlodipine to increase the dissolution rate at higher gastric pH conditions." | 5.33 | Effects of amlodipine orotate on hypertension-related complications in spontaneously hypertensive rats. ( Ahn, BO; Choi, SM; Kim, JE; Kwon, JW, 2006) |
| "Body weight was measured weekly in all the groups, and arterial blood pressure was also measured in all the 10-, 15-, 20-, and 25-week-old SHR by the tail cuff method." | 5.32 | Effect of dietary calcium supplements and amlodipine on growth, arterial blood pressure, and cardiac hypertrophy of spontaneously hypertensive rats. ( Aleixandre, A; Civantos, B, 2003) |
| " The aim of this study was to evaluate the effects of a fixed-dose olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation compared to singles monotherapies." | 5.19 | Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2014) |
| "To evaluate the safety and efficacy of a fixed olmesartan/amlodipine (Olme/Amlo) combination in improving blood pressure control, lipid profile, insulin sensitivity and some inflammatory and insulin resistance markers." | 5.17 | Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2013) |
| " This study evaluated the effects of an olmesartan/amlodipine single pill combination compared to olmesartan or amlodipine monotherapies on BP, lipid profile, insulin resistance, and insulin sensitivity parameters." | 5.17 | Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2013) |
| " The aim of this study was to evaluate the effects of losartan or amlodipine alone or combined with simvastatin on hepatic steatosis degree, and on insulin sensitivity in normocholesterolemic, hypertensive patients with nonalcoholic hepatic steatosis." | 5.16 | Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2012) |
| "This community-based study assessed whether there were age, sex, or racial differences in response to amlodipine 5 to 10 mg once daily in patients with mild to moderate essential hypertension." | 5.08 | Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. ( DiBona, GF; Gaffney, M; Kloner, RA; Sowers, JR; Wein, M, 1996) |
| "The authors studied the efficacy and safety of a long half-life dihydropyridine calcium-antagonist--amlodipine--in a single daily dose in the treatment of isolated systolic hypertension in the elderly." | 5.07 | [Amlodipine in isolated systolic hypertension in the aged]. ( Cosentino, N; Mariani, L; Marino, M; Torrisi, G, 1993) |
| " Metformin treatment improved the insulin sensitivity, and normalized the in vitro bladder hypercontractility and cystometric dysfunction in obese mice." | 3.78 | Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice. ( Anhê, GF; Antunes, E; Calixto, MC; De Nucci, G; Grant, AD; Leiria, LO; Lintomen, L; Mónica, FZ; Sollon, C; Zanesco, A, 2012) |
| "SHR/NDmcr-cp (SHRcp), a rat model of human metabolic syndrome, were divided into four groups, and were administered (i) vehicle, (ii) candesartan (an ARB) 0." | 3.78 | Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Ogawa, H; Sueta, D; Toyama, K; Yamamoto, E; Yasuda, O, 2012) |
| "These data suggest that cilnidipine suppressed the development of proteinuria greater than amlodipine possibly through inhibiting N-type calcium channel-dependent podocyte injury in SHR/ND." | 3.76 | Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. ( Asanuma, K; Fan, YY; Fujita, T; Hitomi, H; Kobori, H; Kohno, M; Nakano, D; Nishiyama, A; Noma, T; Ohashi, N; Ohsaki, H; Suwarni, D; Tomino, Y, 2010) |
| "Although calcium channel blockers have not been shown to be beneficial for the treatment of patients with heart failure, a recent clinical trial demonstrated a favorable effect of amlodipine on the survival of patients with heart failure resulting from nonischemic dilated cardiomyopathy." | 3.69 | Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. ( Matsui, S; Matsumori, A; Okada, I; Sasayama, S; Sato, Y; Shioi, T; Shiota, K; Suzuki, H; Wang, WZ; Yamada, T, 1997) |
| " The pressor response to norepinephrine and angiotensin II, as well as several other blood pressure modulating factors, were studied in normal subjects (n = 9) and patients with essential hypertension (n = 10) before and after 8 weeks of treatment with the long-acting dihydropyridine amlodipine." | 3.68 | Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II. ( Beretta-Piccoli, C; Bühler, FR; Donati, L; Heinen, G; Kusch, F, 1992) |
| " In conclusion, this study has quantitatively described the pharmacokinetic interaction between simvastatin and amlodipine using a modeling approach." | 2.79 | Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine. ( Jang, SB; Lee, D; Lim, LA; Park, K; Roh, H; Son, H, 2014) |
| "Reasonable sampling scheme is the important basis for establishing reliable population pharmacokinetic model." | 2.77 | [Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine]. ( Barrett, JS; Di, W; Guo, R; Huang, ZJ; Jing, NN; Ng, CM; Pei, Q; Yang, GP; Yuan, H; Zhang, BK; Zhou, YN; Zuo, XC, 2012) |
| "Seventy type 2 diabetes mellitus patients with hypertension were enrolled and randomly divided into two groups." | 2.74 | Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohira, M; Oyama, T; Saiki, A; Shirai, K; Yamaguchi, T, 2009) |
| "New-onset diabetes mellitus was defined from adverse event reports, information about new antidiabetic medication and/or a fasting glucose >or=7." | 2.73 | Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial. ( Aksnes, TA; Hua, TA; Julius, S; Kjeldsen, SE; Rostrup, M; Störset, O, 2008) |
| " Amlodipine did not affect cardiac function in the young, and with chronic dosing decreased the heart rate by 3-5 bpm and the cardiac index by 0." | 2.72 | Sympatho-excitatory responses to once-daily dihydropyridines in young versus older hypertensive patients: amlodipine versus felodipine extended release. ( Coletta, E; Leenen, FH; White, R, 2006) |
| "Hypertension is a prevalent disease among African Americans, and successful treatment rates are low." | 2.69 | Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. ISHIB Investigators Group. International Society on Hypertension in Blacks. ( Flack, JM; Hall, WD; Preisser, J; Reed, JW; Yunis, C, 1998) |
| "Arthritis and hypertension are frequent comorbidities in the elderly hypertensive population." | 2.69 | Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. ( Anderson, A; Bertram, D; Morgan, TO, 2000) |
| "Amiloride treatment also reduced high blood pressure caused by the high-salt diet in these mice." | 1.38 | Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice. ( Chen, S; Cui, Y; Jiang, J; Peng, J; Shen, J; Wang, W; Wu, Q, 2012) |
| "Hypercholesterolemia is a common accompaniment of atherosclerosis and may be associated with cardiac hypertrophy." | 1.35 | Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. ( Kang, BY; Mehta, JL; Palade, P; Sharma, SG; Wang, W, 2009) |
| "Amlodipine orotate was prepared by reacting orotic acid and amlodipine to increase the dissolution rate at higher gastric pH conditions." | 1.33 | Effects of amlodipine orotate on hypertension-related complications in spontaneously hypertensive rats. ( Ahn, BO; Choi, SM; Kim, JE; Kwon, JW, 2006) |
| "Body weight was measured weekly in all the groups, and arterial blood pressure was also measured in all the 10-, 15-, 20-, and 25-week-old SHR by the tail cuff method." | 1.32 | Effect of dietary calcium supplements and amlodipine on growth, arterial blood pressure, and cardiac hypertrophy of spontaneously hypertensive rats. ( Aleixandre, A; Civantos, B, 2003) |
| "The effect of long-term administration of amlodipine and cilnidipine was examined on the histopathology and 1,4-dihydropyridine (DHP) calcium channel antagonist receptors in the left ventricle of BIO TO-2 hamsters, a model of dilated cardiomyopathy (DCM)." | 1.31 | Improvement in the histopathology of hearts from cardiomyopathic BIO TO-2 hamsters following long-term administration of amlodipine and cilnidipine. ( Hirano, K; Kimura, R; Ohashi, K; Urayama, A; Watanabe, H; Yamada, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (25.53) | 18.2507 |
| 2000's | 21 (44.68) | 29.6817 |
| 2010's | 13 (27.66) | 24.3611 |
| 2020's | 1 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| van der Vossen, AC | 1 |
| Cransberg, K | 1 |
| de Winter, BCM | 1 |
| Schreuder, MF | 1 |
| van Rooij-Kouwenhoven, RWG | 1 |
| Vulto, AG | 1 |
| Hanff, LM | 1 |
| Derosa, G | 4 |
| Cicero, AF | 3 |
| Carbone, A | 3 |
| Querci, F | 3 |
| Fogari, E | 3 |
| D'Angelo, A | 3 |
| Maffioli, P | 4 |
| Son, H | 1 |
| Lee, D | 1 |
| Lim, LA | 1 |
| Jang, SB | 1 |
| Roh, H | 1 |
| Park, K | 1 |
| Gjorgjievska, K | 1 |
| Zafirov, D | 1 |
| Jurhar-Pavlova, M | 1 |
| Cekovska, S | 1 |
| Atanasovska, E | 1 |
| Pavlovska, K | 1 |
| Zendelovska, D | 1 |
| Aksnes, TA | 1 |
| Kjeldsen, SE | 1 |
| Rostrup, M | 1 |
| Störset, O | 1 |
| Hua, TA | 1 |
| Julius, S | 1 |
| Choi, SM | 2 |
| Seo, MJ | 1 |
| Kang, KK | 1 |
| Kim, JH | 1 |
| Ahn, BO | 2 |
| Yoo, M | 1 |
| Kang, BY | 1 |
| Wang, W | 2 |
| Palade, P | 1 |
| Sharma, SG | 1 |
| Mehta, JL | 1 |
| Miyashita, Y | 1 |
| Saiki, A | 1 |
| Endo, K | 1 |
| Ban, N | 1 |
| Yamaguchi, T | 1 |
| Kawana, H | 1 |
| Nagayama, D | 1 |
| Ohira, M | 1 |
| Oyama, T | 1 |
| Shirai, K | 1 |
| Fan, YY | 1 |
| Kohno, M | 1 |
| Nakano, D | 1 |
| Ohsaki, H | 1 |
| Kobori, H | 1 |
| Suwarni, D | 1 |
| Ohashi, N | 1 |
| Hitomi, H | 1 |
| Asanuma, K | 1 |
| Noma, T | 1 |
| Tomino, Y | 1 |
| Fujita, T | 1 |
| Nishiyama, A | 1 |
| Marçal, DM | 1 |
| Rizzi, E | 1 |
| Martins-Oliveira, A | 1 |
| Ceron, CS | 1 |
| Guimaraes, DA | 1 |
| Gerlach, RF | 1 |
| Tanus-Santos, JE | 1 |
| Fogari, R | 1 |
| Mugellini, A | 1 |
| Zoppi, A | 1 |
| Lazzari, P | 1 |
| Shen, J | 1 |
| Cui, Y | 1 |
| Jiang, J | 1 |
| Chen, S | 1 |
| Peng, J | 1 |
| Wu, Q | 1 |
| Sueta, D | 1 |
| Nakamura, T | 1 |
| Dong, YF | 1 |
| Kataoka, K | 1 |
| Koibuchi, N | 1 |
| Yamamoto, E | 1 |
| Toyama, K | 1 |
| Yasuda, O | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Zuo, XC | 1 |
| Yuan, H | 1 |
| Zhang, BK | 1 |
| Ng, CM | 1 |
| Barrett, JS | 1 |
| Yang, GP | 1 |
| Huang, ZJ | 1 |
| Pei, Q | 1 |
| Guo, R | 1 |
| Zhou, YN | 1 |
| Jing, NN | 1 |
| Di, W | 1 |
| Leiria, LO | 1 |
| Sollon, C | 1 |
| Calixto, MC | 1 |
| Lintomen, L | 1 |
| Mónica, FZ | 1 |
| Anhê, GF | 1 |
| De Nucci, G | 1 |
| Zanesco, A | 1 |
| Grant, AD | 1 |
| Antunes, E | 1 |
| Weber, MA | 1 |
| Jamerson, K | 1 |
| Bakris, GL | 1 |
| Weir, MR | 1 |
| Zappe, D | 1 |
| Zhang, Y | 1 |
| Dahlof, B | 1 |
| Velazquez, EJ | 1 |
| Pitt, B | 1 |
| Kanno, Y | 3 |
| Okada, H | 3 |
| Moriwaki, K | 1 |
| Nagao, S | 1 |
| Takahashi, H | 1 |
| Suzuki, H | 4 |
| Civantos, B | 1 |
| Aleixandre, A | 1 |
| Oshima, T | 1 |
| Ono, N | 1 |
| Ozono, R | 1 |
| Higashi, Y | 1 |
| Ishida, M | 1 |
| Ishida, T | 1 |
| Miho, N | 1 |
| Nakashima, H | 1 |
| Yano, Y | 1 |
| Kambe, M | 1 |
| Lehfeld, LS | 1 |
| Silveira, LA | 1 |
| Ghini, B | 1 |
| Lopes de Faria, JB | 1 |
| Liebisch, B | 1 |
| Celik, T | 1 |
| Kayir, H | 1 |
| Ceyhan, M | 1 |
| Demirtaş, S | 1 |
| Coşar, A | 1 |
| Uzbay, IT | 1 |
| Bernobich, E | 1 |
| Cosenzi, A | 1 |
| Campa, C | 1 |
| Zennaro, C | 1 |
| Sasso, F | 1 |
| Paoletti, S | 1 |
| Bellini, G | 1 |
| Ahokas, RA | 1 |
| Sun, Y | 1 |
| Bhattacharya, SK | 1 |
| Gerling, IC | 1 |
| Weber, KT | 1 |
| Oron-Herman, M | 1 |
| Sela, BA | 1 |
| Rosenthal, T | 1 |
| Leenen, FH | 1 |
| Coletta, E | 1 |
| White, R | 1 |
| Toba, H | 1 |
| Nakagawa, Y | 1 |
| Miki, S | 1 |
| Shimizu, T | 1 |
| Yoshimura, A | 1 |
| Inoue, R | 1 |
| Asayama, J | 1 |
| Kobara, M | 1 |
| Nakata, T | 1 |
| Kim, JE | 1 |
| Kwon, JW | 1 |
| Saruta, T | 2 |
| Mariani, L | 1 |
| Marino, M | 1 |
| Cosentino, N | 1 |
| Torrisi, G | 1 |
| Dworkin, LD | 1 |
| Tolbert, E | 1 |
| Recht, PA | 1 |
| Hersch, JC | 1 |
| Feiner, H | 1 |
| Levin, RI | 1 |
| Kloner, RA | 1 |
| Sowers, JR | 1 |
| DiBona, GF | 1 |
| Gaffney, M | 1 |
| Wein, M | 1 |
| Ikenaga, H | 1 |
| Ishii, N | 1 |
| Itoh, H | 1 |
| Wang, WZ | 1 |
| Matsumori, A | 1 |
| Yamada, T | 1 |
| Shioi, T | 1 |
| Okada, I | 1 |
| Matsui, S | 1 |
| Sato, Y | 1 |
| Shiota, K | 1 |
| Sasayama, S | 1 |
| Huang, W | 1 |
| Alhenc Gelas, F | 1 |
| Osborne-Pellegrin, MJ | 1 |
| Watanabe, M | 1 |
| Kawaguchi, H | 1 |
| Onozuka, H | 1 |
| Mikami, T | 1 |
| Urasawa, K | 1 |
| Okamoto, H | 1 |
| Watanabe, S | 1 |
| Abe, K | 1 |
| Kitabatake, A | 1 |
| Hall, WD | 1 |
| Reed, JW | 1 |
| Flack, JM | 1 |
| Yunis, C | 1 |
| Preisser, J | 1 |
| Karam, H | 1 |
| Clozel, JP | 1 |
| Bruneval, P | 1 |
| Gonzalez, MF | 1 |
| Ménard, J | 1 |
| Atarashi, K | 1 |
| Takagi, M | 1 |
| Minami, M | 1 |
| Ishiyama, A | 1 |
| Urayama, A | 1 |
| Yamada, S | 1 |
| Hirano, K | 1 |
| Kimura, R | 1 |
| Watanabe, H | 1 |
| Ohashi, K | 1 |
| De Luca, N | 1 |
| Izzo, R | 1 |
| Fontana, D | 1 |
| Iovino, G | 1 |
| Argenziano, L | 1 |
| Vecchione, C | 1 |
| Trimarco, B | 1 |
| Morgan, TO | 1 |
| Anderson, A | 1 |
| Bertram, D | 1 |
| Otsuka, F | 1 |
| Ogura, T | 1 |
| Kataoka, H | 1 |
| Kishida, M | 1 |
| Takahashi, M | 1 |
| Mimura, Y | 1 |
| Yamauchi, T | 1 |
| Makino, H | 1 |
| Loke, KE | 1 |
| Messina, EJ | 1 |
| Mital, S | 1 |
| Hintze, TH | 1 |
| Donati, L | 1 |
| Bühler, FR | 1 |
| Beretta-Piccoli, C | 1 |
| Kusch, F | 1 |
| Heinen, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients With Hypertension: Prospective, Multicenter, Observational Study[NCT03255551] | 50 participants (Actual) | Observational | 2014-01-01 | Completed | |||
| A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950] | Phase 3 | 11,506 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 5.0 |
| Benazepril/Hydrochlorothiazide | 6.3 |
Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 8.6 |
| Benazepril/Hydrochlorothiazide | 10.3 |
CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an event (Number) |
|---|---|
| Benazepril/Amlodipine | 9.6 |
| Benazepril/Hydrochlorothiazide | 11.8 |
16 trials available for amlodipine and Body Weight
| Article | Year |
|---|---|
Use of amlodipine oral solution for the treatment of hypertension in children.
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Body Weight; Child; Child, Preschool; Fem | 2020 |
Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies.
Topics: Adipokines; Amlodipine; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Double-Blind Me | 2013 |
Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine.
Topics: Administration, Oral; Adult; Age Factors; Amlodipine; Biological Availability; Body Weight; Calcium | 2014 |
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation.
Topics: Amlodipine; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Do | 2014 |
Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Glucose; Blood P | 2008 |
Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Ankle; Antih | 2009 |
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Body Mass Index; Body Weight; Double-Blind Meth | 2013 |
[Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine].
Topics: Adult; Age Factors; Alanine Transaminase; Amlodipine; Antihypertensive Agents; Bayes Theorem; Body W | 2012 |
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Body Mass Index; Body Size; Body Weight; Ca | 2013 |
Sympatho-excitatory responses to once-daily dihydropyridines in young versus older hypertensive patients: amlodipine versus felodipine extended release.
Topics: Adult; Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Blood Pressure; Body Wei | 2006 |
[Amlodipine in isolated systolic hypertension in the aged].
Topics: Age Factors; Aged; Amlodipine; Body Weight; Calcium Channel Blockers; Drug Evaluation; Female; Human | 1993 |
Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Black People; Bloo | 1996 |
Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. ISHIB Investigators Group. International Society on Hypertension in Blacks.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black People; Blood Pressure; Body Weight; Calcium | 1998 |
Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Glucose; Body Weight; Double-Blind Method; F | 2000 |
Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; | 2000 |
31 other studies available for amlodipine and Body Weight
| Article | Year |
|---|---|
Protective effects of AT1-receptor blocker and CA antagonist combination on renal function in salt loaded spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Body Weight; Calcium C | 2015 |
Beneficial effects of the combination of amlodipine and losartan for lowering blood pressure in spontaneously hypertensive rats.
Topics: Acetylcholine; Administration, Oral; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; A | 2009 |
Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine.
Topics: Amlodipine; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Cardiomegaly; Cholestero | 2009 |
Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.
Topics: Amlodipine; Animals; Base Sequence; Blood Glucose; Blood Pressure; Body Weight; Calcium Channel Bloc | 2010 |
Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension.
Topics: Amlodipine; Animals; Antioxidants; Aorta, Thoracic; Blood Pressure; Body Weight; Calcium Channel Blo | 2011 |
Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice.
Topics: Aldosterone; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensi | 2012 |
Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Bl | 2012 |
Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice.
Topics: Adiposity; Amlodipine; Animals; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Cal | 2012 |
The effects of antihypertensive agents on the survival rate of polycystic kidney disease in Han:SPRD rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Body Weight; Kidney; Kid | 2002 |
Effect of dietary calcium supplements and amlodipine on growth, arterial blood pressure, and cardiac hypertrophy of spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Calcium, Dietary; Cardio | 2003 |
Effect of amlodipine and cilazapril treatment on platelet Ca2+ handling in spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Platel | 2003 |
Early blood pressure normalization independent of the class of antihypertensive agent prevents augmented renal fibronectin and albuminuria in experimental diabetic nephropathy.
Topics: Albuminuria; Amlodipine; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weigh | 2004 |
[Case report: hypertension after stroke].
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Basal Ganglia Cerebrovascular Disease; | 2004 |
CPP and amlodipine alter the decrease in basal acetylcholine and choline release by audiogenic stimulus in hippocampus of ethanol-withdrawn rats in vivo.
Topics: Acetylcholine; Acoustic Stimulation; Alcohol-Induced Disorders, Nervous System; Amlodipine; Animals; | 2004 |
Antihypertensive treatment and renal damage: amlodipine exerts protective effect through the polyol pathway.
Topics: Administration, Oral; Amlodipine; Animals; Blood Glucose; Blood Pressure; Body Weight; Collagen Type | 2004 |
Aldosteronism and a proinflammatory vascular phenotype: role of Mg2+, Ca2+, and H2O2 in peripheral blood mononuclear cells.
Topics: Acetylcysteine; Amlodipine; Animals; Biomarkers; Body Weight; Calcium; Dietary Supplements; Hydrogen | 2005 |
Risk reduction therapy for syndrome X: comparison of several treatments.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Blood Pressure; Body Weight; Captopril; F | 2005 |
Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Antihyperte | 2005 |
Effects of amlodipine orotate on hypertension-related complications in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Calcium; Cardiomegaly; Ce | 2006 |
Renal protective effects of amlodipine on partially nephrectomized spontaneously hypertensive rats fed a high-salt diet.
Topics: Amlodipine; Animals; Blood Pressure; Body Weight; Hypertension; Kidney; Kidney Diseases; Nephrectomy | 1994 |
Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Desoxycorticosterone; Glo | 1996 |
Does combined therapy of Ca-channel blocker and angiotensin converting enzyme inhibitor exceed monotherapy in renal protection against hypertensive injury in rats?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Calcium | 1996 |
Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production.
Topics: Amlodipine; Animals; Body Weight; Calcium Channel Blockers; Cardiovirus Infections; Disease Models, | 1997 |
Protection of the arterial internal elastic lamina by inhibition of the renin-angiotensin system in the rat.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Animals; Aorta, Abdominal; Ao | 1998 |
Chronic effects of enalapril and amlodipine on cardiac remodeling in cardiomyopathic hamster hearts.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Calcium; Calcium Channel | 1998 |
Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats.
Topics: Amlodipine; Analysis of Variance; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Ca | 1999 |
Effects of alacepril and amlodipine on the renal injury induced by a high-cholesterol diet in rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Calcium | 1999 |
Improvement in the histopathology of hearts from cardiomyopathic BIO TO-2 hamsters following long-term administration of amlodipine and cilnidipine.
Topics: Amlodipine; Animals; Animals, Inbred Strains; Body Weight; Calcium Channel Blockers; Calcium Channel | 2000 |
Differential effect of chronic inhibition of calcium channel and angiotensin II type 1-receptor on aldosterone synthesis in spontaneously hypertensive rats.
Topics: Adrenal Cortex; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive | 2000 |
Impaired nitric oxide modulation of myocardial oxygen consumption in genetically cardiomyopathic hamsters.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Bradykinin; Cardiomyopat | 2000 |
Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II.
Topics: Adult; Amlodipine; Angiotensin II; Antihypertensive Agents; Blood Pressure; Body Weight; Dose-Respon | 1992 |